Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation

References

• Wang Z, Yang L, Song X-Q. Oral GS-441524 derivatives: next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol. 2022;13:1015355. doi:10.3389/fimmu.2022.1015355
   PubMed Web of Science ®Google Scholar
• Sasaki M, Tabata K, Kishimoto M, et al. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Sci Trans Med. 2022;15(679):eabq4064. doi:10.1126/scitranslmed.abq4064
   Web of Science ®Google Scholar
• Yang L, Wang Z. Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China. Eur J Med Chem. 2023;257:115503. doi:10.1016/j.ejmech.2023.115503
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi:10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr. 2021;15(6):102329. doi:10.1016/j.dsx.2021.102329
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi:10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Evans A, Qi C, Adebayo JO, et al. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study. J Infect. 2023;86(4):352–360. doi:10.1016/j.jinf.2023.02.012
   PubMed Web of Science ®Google Scholar
• Mutoh Y, Umemura T, Nishikawa T, et al. Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a community setting. Viruses. 2023;15(3):811. doi:10.3390/v15030811
   PubMed Web of Science ®Google Scholar
• Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213–1222. doi:10.1016/S0140-6736(22)01586-0
   PubMed Web of Science ®Google Scholar
• Kwok WC, Tam AR, Ho JCM, et al. Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVID-19). Clin Respir J. 2022;16(4):293–300. doi:10.1111/crj.13480
   PubMed Web of Science ®Google Scholar
• Gomez Antunez M, Muino Miguez A, Bendala Estrada AD, et al. Clinical characteristics and prognosis of COPD patients hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis. 2020;15:3433–3445. doi:10.2147/COPD.S276692
   PubMed Web of Science ®Google Scholar
• Choi H, Lee H, Lee SK, et al. Impact of bronchiectasis on susceptibility to and severity of COVID-19: a nationwide cohort study. Ther Adv Respir Dis. 2021;15:1753466621995043. doi:10.1177/1753466621995043
   Web of Science ®Google Scholar
• Cilli A, Hanta I, Uzer F, et al. Characteristics and outcomes of COVID-19 patients with IPF: a multi-center retrospective study. Respir Med Res. 2022;81:100900. doi:10.1016/j.resmer.2022.100900
   PubMedGoogle Scholar
• Kwok WC, Tsoi MF, Leung SHI, et al. Real-world study on effectiveness of molnupiravir and nirmatrelvir-ritonavir in unvaccinated patients with chronic respiratory diseases with confirmed SARS-CoV-2 infection managed in out-patient setting. Viruses. 2023;15(3). doi:10.3390/v15030610
   Web of Science ®Google Scholar
• Foster City CBGS, Inc. Veklury. US FDA approved product information; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf. Accessed January 4, 2023.
   Google Scholar
• Wan EYF, Yan VKC, Mok AHY, et al. Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a target trial emulation study. Ann Intern Med. 2023;176(4):505–514. doi:10.7326/M22-3057
   PubMed Web of Science ®Google Scholar
• Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681–1693. doi:10.1016/S1473-3099(22)00507-2
   PubMed Web of Science ®Google Scholar
• FDA. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid™. FDA, editor. The United States Food and Drug Administration (FDA); 2022.
   Google Scholar
• FDA. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Lagevrio™ (Molnupiravir) Capsules. FDA, editor. The United States Food and Drug Administration (FDA); 2021.
   Google Scholar
• EMA. Summary of Product Characteristics - Nirmatrelvir-Ritonavir. EMA, editor. European Medicines Agency (EMA); 2022.
   Google Scholar
• EMA. Conditions of Use, Conditions for Distribution and Patients Targeted and Conditions for Safety Monitoring Addressed to Member States for Unauthorised Product Lagevrio (Molnupiravir) Available for Use. EMA, editor. European Medicines Agency (EMA); 2022.
   Google Scholar
• Amani B, Akbarzadeh A, Amani B, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: a systematic review and meta-analysis. J Med Virol. 2023;95(6):e28889. doi:10.1002/jmv.28889
   PubMed Web of Science ®Google Scholar
• HA CCIDER. Interim Recommendation on Clinical Management of Adult Cases with Coronavirus Disease 2019 (COVID-19). Hospital Authority Central Committee on Infectious Disease and Emergency Responses (HA CCIDER); 2023.
   Google Scholar
• NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health (NIH); 2023.
   Google Scholar
• Ye Y, Hubbard R, Li GH, et al. Validation of diagnostic coding for interstitial lung diseases in an electronic health record system in Hong Kong. Pharmacoepidemiol Drug Saf. 2022;31(5):519–523. doi:10.1002/pds.5421
   PubMed Web of Science ®Google Scholar
• Kwok WC, Tam TCC, Sing CW, Chan EWY, Cheung CL. Validation of diagnostic coding for bronchiectasis in an electronic health record system in Hong Kong. Pharmacoepidemiol Drug Saf. 2023;32(10):1077–1082. doi:10.1002/pds.5638
   PubMed Web of Science ®Google Scholar
• Kwok WC, Tam TCC, Sing CW, Chan EWY, Cheung CL. Validation of diagnostic coding for asthma in an electronic health record system in Hong Kong. J Asthma Allergy. 2023;16:315–321. doi:10.2147/JAA.S405297
   PubMed Web of Science ®Google Scholar
• HA CCIDER. Interim Recommendation on Clinical Management of Adult Cases with Coronavirus Disease 2019 (COVID-19). Hospital Authority Central Committee on Infectious Disease and Emergency Responses (HA CCIDER); 2022.
   Google Scholar
• WHO. COVID-19 Clinical Management Living Guidance. Vol. 3. 3rd ed. WHO, editor. World Health Organization (WHO); 2021:116.
   Google Scholar
• Del Borgo C, Garattini S, Bortignon C, et al. Effectiveness, tolerability and prescribing choice of antiviral molecules molnupiravir, remdesivir and nirmatrelvir/r: a real-world comparison in the first ten months of use. Viruses. 2023;15(4):1025. doi:10.3390/v15041025
   PubMed Web of Science ®Google Scholar
• Tiseo G, Barbieri C, Galfo V, et al. Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-world cohort of outpatients with COVID-19 at high risk of progression: the PISA outpatient clinic experience. Infect Dis Ther. 2023;12(1):257–271. doi:10.1007/s40121-022-00729-2
   PubMed Web of Science ®Google Scholar